Sign In
Buy NKGN
$0.0600
+0 (+0%)
At Close: Jun 03, 2026
NKGen Biotech to Present at the Alzheimer's Association International Conference 2025
08:05am, Tuesday, 22'nd Jul 2025
SANTA ANA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercia
NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan
04:05pm, Thursday, 17'th Jul 2025
In connection with HekaBio's recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial development of NKGen's autologous NK cell the
NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards
05:45pm, Wednesday, 16'th Jul 2025
Funding in the amount of $2.0M from Japanese strategic investor, in the form of common equity PIPE with warrants. New funding provides for necessary resources to regain compliance with reporting oblig
SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercia
SANTA ANA, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercia
NKGen Biotech Chairman & CEO Paul Y. Song, M.D.
08:05am, Thursday, 08'th May 2025
New funding from Dr. Song augments $3.0 million in funding advances from AlpineBrook Capital in 2025 above and beyond the $5.5 million proceeds and additional $4 million commitments in previously-disc
SANTA ANA, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commerci
Moderate Alzheimer's disease (AD) patients in the trial received the highest dose of troculeucel to date at 6 billion cells per treatment.
SANTA ANA, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commerci
NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented
01:00pm, Tuesday, 04'th Mar 2025
SANTA ANA, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologo
SANTA ANA, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and comme
NKGen takes a meaningful step towards potential treatment for frontotemporal dementia (“FTD”) patients with limited treatment options. NKGen takes a meaningful step towards potential treatment for
SANTA ANA, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commer
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer's Disease
08:00am, Thursday, 13'th Feb 2025
The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse events following troculeucel therapy. Troculeucel ther
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer's Disease
08:00am, Wednesday, 12'th Feb 2025
The Fast Track designation accelerates troculeucel's path to U.S. FDA submission for the treatment of patients with moderate Alzheimer's disease. NKGen will benefit from increased FDA interactions, en
